Key stats
About Invesco Biotechnology & Genome ETF
Home page
Inception date
Jun 23, 2005
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Invesco Capital Management LLC
Distributor
Invesco Distributors, Inc.
PBE is not a pure-play biotech fund, it goes beyond the scope of pure biotech firms and includes companies that benefit significantly from advances in biotech and genetic engineering. This causes PBE to differ from other biotech ETFs, therefore, it is important to note the funds portfolio before investing. Moreover, far from a plain-vanilla approach, PBE's underlying index uses a multifactor system (price momentum, earnings momentum, quality: ROE, asset turnover, FCF margin), management action, and value) to select 30 US stocks and weights them in tiers. The tiered weighting scheme creates a small-cap tilt. Top-ranked larger stocks receive 40% of index weight while the top-ranked smaller stocks are given 60%. The approach produces a unique portfolio of biotech and peripheral-industry companies. The fund is rebalanced and reconstituted quarterly starting each February. Prior to August 28, 2023, the fund traded under the name Invesco Dynamic Biotechnology & Genome ETF.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.93%
Health Technology99.93%
Bonds, Cash & Other0.07%
Mutual fund0.06%
Cash0.00%
Stock breakdown by region
North America97.24%
Europe2.76%
Latin America0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
PBE top holdings are Alnylam Pharmaceuticals, Inc and Royalty Pharma Plc Class A, occupying 5.16% and 5.02% of the portfolio correspondingly.
PBE last dividends amounted to 0.03 USD. The quarter before, the issuer paid 0.01 USD in dividends, which shows a 75.98% increase.
PBE assets under management is 226.64 M USD. It's risen 6.61% over the last month.
PBE fund flows account for −29.40 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, PBE pays dividends to its holders with the dividend yield of 0.07%. The last dividend (Mar 28, 2025) amounted to 0.03 USD. The dividends are paid quarterly.
PBE shares are issued by Invesco Ltd. under the brand Invesco. The ETF was launched on Jun 23, 2005, and its management style is Passive.
PBE expense ratio is 0.58% meaning you'd have to pay 0.58% of your investment to help manage the fund.
PBE follows the Dynamic Biotech & Genome Intellidex Index (AMEX). ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
PBE invests in stocks.
PBE price has risen by 8.35% over the last month, and its yearly performance shows a 1.86% increase. See more dynamics on PBE price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 2.71% over the last month, showed a −2.27% decrease in three-month performance and has increased by 1.22% in a year.
NAV returns, another gauge of an ETF dynamics, have risen by 2.71% over the last month, showed a −2.27% decrease in three-month performance and has increased by 1.22% in a year.
PBE trades at a premium (0.05%) meaning the ETF is trading at a higher price than the calculated NAV.